VBL's psoriasis drug candidate meets primary goals in Phase II trial

03/19/2012 | Business Wire

VBL Therapeutics' drug candidate VB-201 significantly reduced vascular inflammation linked to atherosclerotic lesions in patients with severe psoriasis 12 weeks after receiving the treatment, according to a Phase II sub-trial that involved the use of PET/CT scans to assess inflammation. The results were presented at a meeting in San Diego.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT